Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cunningham

Showing results (341-350 of 621) with videos related to

Pageof 63
Sort By:
BMC Hematology|August 22, 2018
Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patientsAndrea Kühnl, David Cunningham, Margaret Hutka, et al.
British Journal of Cancer|December 20, 2023
Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trialBianca Grosser, Jake Emmerson, Nic G Reitsam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancerIan Chau, Gina Brown, David Cunningham, et al.
Frontiers in Neuroscience|February 19, 2026
Evaluation of the myogenic effects of subthalamic nucleus deep brain stimulation at near therapeutic amplitudesCarmen Toth, Brett A Campbell, Leonardo Favi Bocca, et al.
Cancer Treatment Reviews|April 12, 2020
Imaging and clinical correlates with regorafenib in metastatic colorectal cancerKhurum Khan, Stefano Cascinu, David Cunningham, et al.
The Lancet. Oncology|September 14, 2013
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialDavid Cunningham, Istvan Lang, Eugenio Marcuello, et al.
JAMA Oncology|May 26, 2018
Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric CancerSheraz R Markar, Tom Wiggins, Stefan Antonowicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331Hugo E R Ford, Fraser Mitchell, David Cunningham, et al.
Clinical Colorectal Cancer|November 9, 2018
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center ExperienceKhurum Khan, Jayant K Rane, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junctionAndrew R Davies, James A Gossage, Janine Zylstra, et al.
Pageof 63

Showing results (341-350 of 621) with videos related to

Sort By:
Pageof 63
BMC Hematology|August 22, 2018
Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patientsAndrea Kühnl, David Cunningham, Margaret Hutka, et al.
British Journal of Cancer|December 20, 2023
Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trialBianca Grosser, Jake Emmerson, Nic G Reitsam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancerIan Chau, Gina Brown, David Cunningham, et al.
Frontiers in Neuroscience|February 19, 2026
Evaluation of the myogenic effects of subthalamic nucleus deep brain stimulation at near therapeutic amplitudesCarmen Toth, Brett A Campbell, Leonardo Favi Bocca, et al.
Cancer Treatment Reviews|April 12, 2020
Imaging and clinical correlates with regorafenib in metastatic colorectal cancerKhurum Khan, Stefano Cascinu, David Cunningham, et al.
The Lancet. Oncology|September 14, 2013
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialDavid Cunningham, Istvan Lang, Eugenio Marcuello, et al.
JAMA Oncology|May 26, 2018
Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric CancerSheraz R Markar, Tom Wiggins, Stefan Antonowicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331Hugo E R Ford, Fraser Mitchell, David Cunningham, et al.
Clinical Colorectal Cancer|November 9, 2018
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center ExperienceKhurum Khan, Jayant K Rane, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junctionAndrew R Davies, James A Gossage, Janine Zylstra, et al.
Pageof 63